Status:

ACTIVE_NOT_RECRUITING

LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2)

Lead Sponsor:

Federal University of São Paulo

Collaborating Sponsors:

Fundação de Amparo à Pesquisa do Estado de São Paulo

Conditions:

Vaginal Atrophy

Vulva; Atrophy

Eligibility:

FEMALE

30-75 years

Phase:

NA

Brief Summary

This is a randomized controlled trial to evaluate the use of LASER, Micro Ablative radiofrequency and topic promestriene to treat symptoms of vulvovaginal atrophy of women treated for breast cancer.

Detailed Description

Women treated for breast cancer with moderate or severe signs or symptoms of vulvovaginal atrophy will be eligible for the study. The patients will be randomized to receive one of the three intravagi...

Eligibility Criteria

Inclusion

  • Women with breast cancer treated with surgery and / or chemotherapy and / or radiotherapy, that has been concluded at least 6 months before inclusion, whether or not using aromatase inhibitor and complaining of vulvovaginal atrophy
  • To present, at least moderate, or severe intensity (score 4 or more of visual analog scale ( 0-10)) of one of the signs or symptoms of vulvovaginal atrophy:
  • Burning
  • Discomfort
  • Dryness
  • Cracks
  • Pruritus
  • Lack of vaginal lubrication
  • Penetration dyspareunia that began at the menopausal or postmenopausal transition
  • Decreased vaginal epithelium turgor and trophism
  • Deletion of mucous and skin folds.
  • Absence of vaginal surgical procedure in the last year
  • Genital prolapse stage no greater than stage II of Pelvic Organs Prolapse Quantitation (POP-Q) with Ba, Bp or C points less than or equal to 0

Exclusion

  • Active genital infection
  • Active infection of HPV (human papillomavirus) or Herpes
  • users of medications with estrogenic effect (digoxin and other chemicals)
  • Postmenopausal genital bleeding
  • uncontrolled diabetes
  • use of multivitamins with zinc
  • use of copper or hormonal IUDs (intrauterine device) at the time of inclusion
  • presence of genitourinary or rectovaginal fistulas

Key Trial Info

Start Date :

September 30 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2025

Estimated Enrollment :

195 Patients enrolled

Trial Details

Trial ID

NCT04081805

Start Date

September 30 2019

End Date

September 1 2025

Last Update

April 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Federal University of Sao Paulo - Unifesp

São Paulo, São Paulo, Brazil, 0-4023- 062